Literature DB >> 19228723

Uncovering growth-suppressive MicroRNAs in lung cancer.

Xi Liu1, Lorenzo F Sempere, Fabrizio Galimberti, Sarah J Freemantle, Candice Black, Konstantin H Dragnev, Yan Ma, Steven Fiering, Vincent Memoli, Hua Li, James DiRenzo, Murray Korc, Charles N Cole, Mads Bak, Sakari Kauppinen, Ethan Dmitrovsky.   

Abstract

PURPOSE: MicroRNA (miRNA) expression profiles improve classification, diagnosis, and prognostic information of malignancies, including lung cancer. This study uncovered unique growth-suppressive miRNAs in lung cancer. EXPERIMENTAL
DESIGN: miRNA arrays were done on normal lung tissues and adenocarcinomas from wild-type and proteasome degradation-resistant cyclin E transgenic mice to reveal repressed miRNAs in lung cancer. Real-time and semiquantitative reverse transcription-PCR as well as in situ hybridization assays validated these findings. Lung cancer cell lines were derived from each transgenic line (designated as ED-1 and ED-2 cells, respectively). Each highlighted miRNA was independently transfected into these cells. Growth-suppressive mechanisms were explored. Expression of a computationally predicted miRNA target was examined. These miRNAs were studied in a paired normal-malignant human lung tissue bank.
RESULTS: miR-34c, miR-145, and miR-142-5p were repressed in transgenic lung cancers. Findings were confirmed by real-time and semiquantitative reverse transcription-PCR as well as in situ hybridization assays. Similar miRNA profiles occurred in human normal versus malignant lung tissues. Individual overexpression of miR-34c, miR-145, and miR-142-5p in ED-1 and ED-2 cells markedly repressed cell growth. Anti-miR cotransfections antagonized this inhibition. The miR-34c target, cyclin E, was repressed by miR-34c transfection and provided a mechanism for observed growth suppression.
CONCLUSIONS: miR-34c, miR-145, and miR-142-5p were repressed in murine and human lung cancers. Transfection of each miRNA significantly repressed lung cancer cell growth. Thus, these miRNAs were growth suppressive and are proposed to exert antineoplastic effects in the lung.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19228723      PMCID: PMC3749890          DOI: 10.1158/1078-0432.CCR-08-1355

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

1.  Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line.

Authors:  James DiRenzo; Sabina Signoretti; Noriaki Nakamura; Ramon Rivera-Gonzalez; William Sellers; Massimo Loda; Myles Brown
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

2.  TM4: a free, open-source system for microarray data management and analysis.

Authors:  A I Saeed; V Sharov; J White; J Li; W Liang; N Bhagabati; J Braisted; M Klapa; T Currier; M Thiagarajan; A Sturn; M Snuffin; A Rezantsev; D Popov; A Ryltsov; E Kostukovich; I Borisovsky; Z Liu; A Vinsavich; V Trush; J Quackenbush
Journal:  Biotechniques       Date:  2003-02       Impact factor: 1.993

3.  Variance stabilization applied to microarray data calibration and to the quantification of differential expression.

Authors:  Wolfgang Huber; Anja von Heydebreck; Holger Sültmann; Annemarie Poustka; Martin Vingron
Journal:  Bioinformatics       Date:  2002       Impact factor: 6.937

Review 4.  The functions of animal microRNAs.

Authors:  Victor Ambros
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

5.  Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism.

Authors:  J Langenfeld; H Kiyokawa; D Sekula; J Boyle; E Dmitrovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

6.  Combinatorial microRNA target predictions.

Authors:  Azra Krek; Dominic Grün; Matthew N Poy; Rachel Wolf; Lauren Rosenberg; Eric J Epstein; Philip MacMenamin; Isabelle da Piedade; Kristin C Gunsalus; Markus Stoffel; Nikolaus Rajewsky
Journal:  Nat Genet       Date:  2005-04-03       Impact factor: 38.330

Review 7.  The utility of LNA in microRNA-based cancer diagnostics and therapeutics.

Authors:  Jan Stenvang; Asli N Silahtaroglu; Morten Lindow; Joacim Elmen; Sakari Kauppinen
Journal:  Semin Cancer Biol       Date:  2008-01-15       Impact factor: 15.707

8.  Reduced accumulation of specific microRNAs in colorectal neoplasia.

Authors:  Michael Z Michael; Susan M O' Connor; Nicholas G van Holst Pellekaan; Graeme P Young; Robert J James
Journal:  Mol Cancer Res       Date:  2003-10       Impact factor: 5.852

9.  Direct labeling of RNA with multiple biotins allows sensitive expression profiling of acute leukemia class predictor genes.

Authors:  Kyle Cole; Vivi Truong; Dale Barone; Glenn McGall
Journal:  Nucleic Acids Res       Date:  2004-06-17       Impact factor: 16.971

10.  Prediction of mammalian microRNA targets.

Authors:  Benjamin P Lewis; I-hung Shih; Matthew W Jones-Rhoades; David P Bartel; Christopher B Burge
Journal:  Cell       Date:  2003-12-26       Impact factor: 41.582

View more
  94 in total

1.  Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene.

Authors:  Jianjun Zhang; Haiyan Guo; He Zhang; Haibo Wang; Guanxiang Qian; Xianqun Fan; Andrew R Hoffman; Ji-Fan Hu; Shengfang Ge
Journal:  Cancer       Date:  2010-08-24       Impact factor: 6.860

Review 2.  Lung injury and lung cancer caused by cigarette smoke-induced oxidative stress: Molecular mechanisms and therapeutic opportunities involving the ceramide-generating machinery and epidermal growth factor receptor.

Authors:  Tzipora Goldkorn; Simone Filosto; Samuel Chung
Journal:  Antioxid Redox Signal       Date:  2014-07-01       Impact factor: 8.401

Review 3.  RNA interference and cancer therapy.

Authors:  Zhaohui Wang; Donald D Rao; Neil Senzer; John Nemunaitis
Journal:  Pharm Res       Date:  2011-10-19       Impact factor: 4.200

Review 4.  Involvement of microRNAs in lung cancer biology and therapy.

Authors:  Xi Liu; Lorenzo F Sempere; Yongli Guo; Murray Korc; Sakari Kauppinen; Sarah J Freemantle; Ethan Dmitrovsky
Journal:  Transl Res       Date:  2011-02-04       Impact factor: 7.012

5.  Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.

Authors:  Fabrizio Galimberti; Sarah L Thompson; Xi Liu; Hua Li; Vincent Memoli; Simon R Green; James DiRenzo; Patricia Greninger; Sreenath V Sharma; Jeff Settleman; Duane A Compton; Ethan Dmitrovsky
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

6.  UBE1L causes lung cancer growth suppression by targeting cyclin D1.

Authors:  Qing Feng; David Sekula; Yongli Guo; Xi Liu; Candice C Black; Fabrizio Galimberti; Sumit J Shah; Lorenzo F Sempere; Vincent Memoli; Jesper B Andersen; Bret A Hassel; Konstantin Dragnev; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

7.  miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer.

Authors:  T Chiyomaru; H Enokida; S Tatarano; K Kawahara; Y Uchida; K Nishiyama; L Fujimura; N Kikkawa; N Seki; M Nakagawa
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

8.  Detecting microRNA activity from gene expression data.

Authors:  Stephen F Madden; Susan B Carpenter; Ian B Jeffery; Harry Björkbacka; Katherine A Fitzgerald; Luke A O'Neill; Desmond G Higgins
Journal:  BMC Bioinformatics       Date:  2010-05-18       Impact factor: 3.169

9.  Retinoic acid mediates long-paced oscillations in retinoid receptor activity: evidence for a potential role for RIP140.

Authors:  Kelly C Heim; Joshua J Gamsby; Mary P Hever; Sarah J Freemantle; Jennifer J Loros; Jay C Dunlap; Michael J Spinella
Journal:  PLoS One       Date:  2009-10-28       Impact factor: 3.240

10.  MicroRNA-145 targets YES and STAT1 in colon cancer cells.

Authors:  Lea H Gregersen; Anders B Jacobsen; Lisa B Frankel; Jiayu Wen; Anders Krogh; Anders H Lund
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.